Abstracts
10 June 2009
Vol. 2 No. 13 (2006)
https://doi.org/10.4081/hmr.v2i13.482
0
0
0
0
Smart Citations
0
0
0
0
Citing PublicationsSupportingMentioningContrasting
View Citations

See how this article has been cited at scite.ai

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

Phase II trial of romidepsin (FK228 or depsipeptide) in peripheral T-cell lymphoma: clinical activity and molecular markers

Authors

RL Piekarz
support@pagepress.org
R Frye
M Turner
J Turner
S Allen
MH Kirschbaum
J Zain
M Prince
Histone deacetylase inhibitors induce changes in gene expression that lead to cellular differentiation and reversal of the transformed phenotype. In addition, acetylation of centromeric chromatin and non-histone proteins also likely plays a role in cytotoxicity due to romi depsin. Interest in clinical development of these agents has been spurred by the responses observed in patients with peripheral or cutaneous T-cell lymphoma to romidepsin, previously FK228 or depsipeptide.

Altmetrics

Downloads

Citations

Crossref
0
Scopus
0
Google Scholar
Europe PMC

Supporting Agencies

How to Cite



Phase II trial of romidepsin (FK228 or depsipeptide) in peripheral T-cell lymphoma: clinical activity and molecular markers. (2009). Hematology Meeting Reports, 2(13). https://doi.org/10.4081/hmr.v2i13.482